首页 > 最新文献

Heart rhythm最新文献

英文 中文
A new dimension in cardiac imaging: Three-dimensional exploration of the atrioventricular conduction axis with hierarchical phase-contrast tomography. 心脏成像的新维度:分层相位对比断层扫描对房室传导轴的三维探索。
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-04 DOI: 10.1016/j.hrthm.2024.10.002
Justin T Tretter, Jayanthi N Koneru, Diane E Spicer, Kenneth A Ellenbogen, Robert H Anderson, Shlomo Ben-Haim

Much of our understanding of the atrioventricular conduction axis has been derived from early 20th-century histologic investigations. These studies, although foundational, are constrained by their 2-dimensional representation of complex 3-dimensional anatomy. The variability in the course of the atrioventricular conduction axis, and its relationship to surrounding cardiac structures, necessitates a more advanced imaging approach. Using hierarchical phase-contrast tomography of an autopsied heart specimen with cellular resolution, this review provides a contemporary understanding of the atrioventricular conduction axis. By correlating these findings with 3-dimensional computed tomographic reconstructions in living patients, we offer clinicians the insights needed accurately to predict the location of the atrioventricular conduction axis. This novel approach overcomes the inherent limitations of 2-dimensional histology, enhancing our ability to understand and visualize the intricate relationships of the conduction axis within the heart.

我们对房室传导轴的了解大多来自 20 世纪早期的组织学研究。这些研究虽然具有奠基性意义,但受限于其对复杂的三维解剖的二维表述。由于房室传导轴的走向及其与周围心脏结构的关系变化多端,因此有必要采用更先进的成像方法。本综述利用具有细胞分辨率的自体心脏标本分层相位对比断层扫描(HiP-CT),提供了对房室传导轴的现代理解。通过将这些发现与在世患者的三维计算机断层扫描重建相关联,我们为临床医生提供了准确预测房室传导轴位置所需的洞察力。这种新方法克服了二维组织学的固有局限性,提高了我们理解和直观显示心脏内传导轴错综复杂关系的能力。
{"title":"A new dimension in cardiac imaging: Three-dimensional exploration of the atrioventricular conduction axis with hierarchical phase-contrast tomography.","authors":"Justin T Tretter, Jayanthi N Koneru, Diane E Spicer, Kenneth A Ellenbogen, Robert H Anderson, Shlomo Ben-Haim","doi":"10.1016/j.hrthm.2024.10.002","DOIUrl":"10.1016/j.hrthm.2024.10.002","url":null,"abstract":"<p><p>Much of our understanding of the atrioventricular conduction axis has been derived from early 20th-century histologic investigations. These studies, although foundational, are constrained by their 2-dimensional representation of complex 3-dimensional anatomy. The variability in the course of the atrioventricular conduction axis, and its relationship to surrounding cardiac structures, necessitates a more advanced imaging approach. Using hierarchical phase-contrast tomography of an autopsied heart specimen with cellular resolution, this review provides a contemporary understanding of the atrioventricular conduction axis. By correlating these findings with 3-dimensional computed tomographic reconstructions in living patients, we offer clinicians the insights needed accurately to predict the location of the atrioventricular conduction axis. This novel approach overcomes the inherent limitations of 2-dimensional histology, enhancing our ability to understand and visualize the intricate relationships of the conduction axis within the heart.</p>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isoproterenol- and pacing-induced changes of J waves unrelated to idiopathic ventricular fibrillation. 异丙肾上腺素和起搏诱导的 J 波变化与特发性室颤无关
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-04 DOI: 10.1016/j.hrthm.2024.09.064
Asami Kashiwa, Yukio Hosaka, Hitoshi Kitazawa, Masaki Okabe, Akinori Sato, Naohiko Takahashi, Yoshifusa Aizawa
{"title":"Isoproterenol- and pacing-induced changes of J waves unrelated to idiopathic ventricular fibrillation.","authors":"Asami Kashiwa, Yukio Hosaka, Hitoshi Kitazawa, Masaki Okabe, Akinori Sato, Naohiko Takahashi, Yoshifusa Aizawa","doi":"10.1016/j.hrthm.2024.09.064","DOIUrl":"10.1016/j.hrthm.2024.09.064","url":null,"abstract":"","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency of and outcomes associated with nonadherence to guideline-based recommendations for an implantable cardioverter-defibrillator in patients with congenital long QT syndrome. 先天性长 QT 综合征患者不遵守基于指南的植入式心律转复除颤器建议的频率和结果。
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-02 DOI: 10.1016/j.hrthm.2024.09.063
Raquel Neves, Lia Crotti, Sahej Bains, J Martijn Bos, Federica Dagradi, Giulia Musu, Ramin Garmany, Fulvio L F Giovenzana, Paolo Cerea, John R Giudicessi, Peter J Schwartz, Michael J Ackerman

Background: Guideline-directed device therapy for long QT syndrome (LQTS) has evolved during the years, and indications for an implantable cardioverter-defibrillator (ICD) vary between professional cardiac societies.

Objective: We aimed to identify the subset of patients with LQTS who satisfied a class I or class II 2022 European Society of Cardiology guideline-based recommendation for an ICD and to determine the outcomes of those patients who received an ICD compared with those treated without an ICD.

Methods: Retrospective analysis was conducted of 2861 patients with LQT1, LQT2, or LQT3 to identify patients meeting contemporary recommendations for guideline-directed device therapy. Basic demographics, clinical characteristics, and frequency/type of breakthrough cardiac events (BCEs) were extracted, and outcomes/complications were compared between patients treated with an ICD and those treated without one.

Results: Of the 290 patients (approximately 10%) who met a guideline-based recommendation, 53 (18%) satisfied a class I/level B indication for an ICD; 56 (19%), a class I/level C indication; 19 (7%), a class IIa/level C indication; and 162 (56%), a class IIb/level B indication. However, most patients (156/290 [54%]) did not receive an ICD. Of those who received an ICD, 55 of 134 (41%) experienced ≥1 appropriate ventricular fibrillation-terminating ICD therapy, whereas ICD-related complications occurred in 13 patients (10%). Of those who were treated without an ICD, only 6 of 156 patients (4%) had nonlethal BCEs, which was significantly lower compared with the ICD group (P < .001).

Conclusion: With >1200 years of combined follow-up, the experience and evidence from our 2 LQTS specialty centers suggest that many patients who satisfy a recommendation for an ICD based on the latest 2022 European Society of Cardiology guidelines may not need one. This is particularly true when the indication stemmed from a BCE while receiving beta blocker therapy or in asymptomatic patients with an increased 1-2-3-LQTS-Risk score.

背景:多年来,长 QT 综合征(LQTS)的指南指导设备治疗(GDDT)不断发展,植入式心律转复除颤器(ICD)的适应症在不同的专业心脏病学会也有所不同:目的:确定符合 2022 年欧洲心脏病学会(ESC)指南推荐的 I 类或 II 类 ICD 的 LQTS 患者子集,并确定与未接受 ICD 治疗的患者相比,接受 ICD 治疗的患者的预后:对 2861 名 LQT1、LQT2 或 LQT3 患者进行回顾性分析,以确定哪些患者符合当代 GDDT 建议。提取了患者的基本人口统计学特征、临床特征和突破性心脏事件(BCEs)的频率/类型,并对使用 ICD 治疗的患者与未使用 ICD 治疗的患者的结果/并发症进行了比较:在符合指南建议的 290 名患者(约占 10%)中,53 人(18%)符合 ICD 的 I 类/B 级适应症,56 人(19%)符合 I 类/C 级适应症,19 人(7%)符合 IIA 类/C 级适应症,165 人(55%)符合 IIB 类/B 级适应症。然而,大多数患者 156/290(54%)没有接受 ICD 治疗。在接受 ICD 治疗的患者中,55/134(41%)例患者经历了≥1 次适当的室颤(VF),导致 ICD 治疗终止,13 例患者(10%)出现了 ICD 相关并发症。在未使用 ICD 治疗的患者中,只有 6/154 例患者(4%)发生了非致命性 BCE,与 ICD 组相比明显较低(p 结论:在超过 1200 年的综合随访中,我们两家 LQTS 专科中心的经验和证据表明,根据最新的 2022 年 ESC 指南,许多符合 ICD 建议的患者可能并不需要 ICD。当适应症源于接受 BB 治疗时的 BCE 或 "1-2-3 LQTS 风险评分 "增加的无症状患者时,情况尤其如此。
{"title":"Frequency of and outcomes associated with nonadherence to guideline-based recommendations for an implantable cardioverter-defibrillator in patients with congenital long QT syndrome.","authors":"Raquel Neves, Lia Crotti, Sahej Bains, J Martijn Bos, Federica Dagradi, Giulia Musu, Ramin Garmany, Fulvio L F Giovenzana, Paolo Cerea, John R Giudicessi, Peter J Schwartz, Michael J Ackerman","doi":"10.1016/j.hrthm.2024.09.063","DOIUrl":"10.1016/j.hrthm.2024.09.063","url":null,"abstract":"<p><strong>Background: </strong>Guideline-directed device therapy for long QT syndrome (LQTS) has evolved during the years, and indications for an implantable cardioverter-defibrillator (ICD) vary between professional cardiac societies.</p><p><strong>Objective: </strong>We aimed to identify the subset of patients with LQTS who satisfied a class I or class II 2022 European Society of Cardiology guideline-based recommendation for an ICD and to determine the outcomes of those patients who received an ICD compared with those treated without an ICD.</p><p><strong>Methods: </strong>Retrospective analysis was conducted of 2861 patients with LQT1, LQT2, or LQT3 to identify patients meeting contemporary recommendations for guideline-directed device therapy. Basic demographics, clinical characteristics, and frequency/type of breakthrough cardiac events (BCEs) were extracted, and outcomes/complications were compared between patients treated with an ICD and those treated without one.</p><p><strong>Results: </strong>Of the 290 patients (approximately 10%) who met a guideline-based recommendation, 53 (18%) satisfied a class I/level B indication for an ICD; 56 (19%), a class I/level C indication; 19 (7%), a class IIa/level C indication; and 162 (56%), a class IIb/level B indication. However, most patients (156/290 [54%]) did not receive an ICD. Of those who received an ICD, 55 of 134 (41%) experienced ≥1 appropriate ventricular fibrillation-terminating ICD therapy, whereas ICD-related complications occurred in 13 patients (10%). Of those who were treated without an ICD, only 6 of 156 patients (4%) had nonlethal BCEs, which was significantly lower compared with the ICD group (P < .001).</p><p><strong>Conclusion: </strong>With >1200 years of combined follow-up, the experience and evidence from our 2 LQTS specialty centers suggest that many patients who satisfy a recommendation for an ICD based on the latest 2022 European Society of Cardiology guidelines may not need one. This is particularly true when the indication stemmed from a BCE while receiving beta blocker therapy or in asymptomatic patients with an increased 1-2-3-LQTS-Risk score.</p>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia. 用于治疗儿茶酚胺能多态性室性心动过速的瑞诺丁受体调节剂的结构活性优化。
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-02 DOI: 10.1016/j.hrthm.2024.09.062
Oliver M Moore, Martha Sibrian-Vazquez, Jose Alberto Navarro-Garcia, Yuriana Aguilar-Sanchez, Mara R Turkieltaub-Paredes, Satadru K Lahiri, Li Ni, Tarah A Word, Christina Y Miyake, Robert M Strongin, Xander H T Wehrens

Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia disorder associated with lethal arrhythmias. Most CPVT cases are caused by inherited variants in the gene encoding ryanodine receptor type 2 (RYR2).

Objective: The goal of this study was to investigate the structure-activity relationship of tetracaine derivatives and to test a lead compound in a mouse model of CPVT.

Methods: We synthesized >200 tetracaine derivatives and characterized 11 of those. The effects of these compounds on Ca2+ handling in cardiomyocytes from R176Q/+ mice was tested with confocal microscopy. The effects of lead compound MSV1302 on arrhythmia inducibility and cardiac contractility were tested by programmed electrical stimulation and echocardiography, respectively. Plasma and microsomal stability and cytotoxicity assays were also performed.

Results: Ca2+ imaging revealed that 3 of 11 compounds suppressed sarcoplasmic reticulum Ca2+ leak through mutant RyR2. Two compounds selected for further testing exhibited a half-maximal effective concentration of 146 nM (MSV1302) and 49 nM (MSV1406). Whereas neither compound altered baseline electrocardiogram intervals, only MSV1302 suppressed stress- and pacing-induced ventricular tachycardia in vivo in R176Q/+ mice. Echocardiography revealed that the lead compound MSV1302 did not negatively affect cardiac inotropy and chronotropy. Finally, compound MSV1302 did not block INa, ICa,L, or IKr; it exhibited excellent stability in plasma and microsomes, and it was not cytotoxic.

Conclusion: Structure-activity relationship studies of second-generation tetracaine derivatives identified lead compound MSV1302 with a favorable pharmacokinetic profile. MSV1302 normalized aberrant RyR2 activity in vitro and in vivo, without altering cardiac inotropy, chronotropy, or off-target effects on other ion channels. This compound may be a strong candidate for future clinical studies to determine its efficacy in CPVT patients.

背景:儿茶酚胺能多态性室性心动过速(CPVT)是一种遗传性心律失常疾病,与潜在的致命性心律失常有关。大多数 CPVT 病例是由 2 型雷诺丁受体(RYR2)基因的遗传变异引起的:研究四卡因衍生物的结构活性关系,并在 CPVT 小鼠模型中测试一种先导化合物:我们合成了超过 200 种四卡因衍生物,并对其中 11 种进行了表征。使用共聚焦显微镜检测了这些化合物对 R176Q/+ 小鼠心肌细胞中 Ca2+ 处理的影响。利用程序电刺激和超声心动图分别测试了先导化合物 MSV1302 对心律失常诱导性和心脏收缩力的影响。此外,还进行了血浆和微粒体稳定性及细胞毒性检测:Ca2+ 成像显示,11 种化合物中有 4 种抑制了通过突变型 RyR2 的肌质网 Ca2+ 泄漏。两种被选作进一步测试的化合物的 EC50 分别为 146 nM(MSV1302)和 49 nM(MSV1406)。虽然这两种化合物都不会改变基线心电图间隔,但只有 MSV1302 能抑制 R176Q/+ 小鼠体内应激和起搏诱发的室性心动过速。超声心动图显示,先导化合物 MSV1302 不会对心脏收缩力和时速产生负面影响。最后,化合物 MSV1302 没有阻断 INa、ICa,L 或 IKr,在血浆和微粒体中表现出良好的稳定性,并且没有细胞毒性:第二代四卡因衍生物的结构活性关系研究发现了具有良好药代动力学特征的先导化合物 MSV1302。MSV1302 可使体外和体内异常的 RyR2 活性正常化,而不会改变心肌收缩力、心动过速或对其他离子通道的脱靶效应。该化合物可能是未来临床研究的有力候选药物,以确定其对 CPVT 患者的疗效。
{"title":"Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia.","authors":"Oliver M Moore, Martha Sibrian-Vazquez, Jose Alberto Navarro-Garcia, Yuriana Aguilar-Sanchez, Mara R Turkieltaub-Paredes, Satadru K Lahiri, Li Ni, Tarah A Word, Christina Y Miyake, Robert M Strongin, Xander H T Wehrens","doi":"10.1016/j.hrthm.2024.09.062","DOIUrl":"10.1016/j.hrthm.2024.09.062","url":null,"abstract":"<p><strong>Background: </strong>Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia disorder associated with lethal arrhythmias. Most CPVT cases are caused by inherited variants in the gene encoding ryanodine receptor type 2 (RYR2).</p><p><strong>Objective: </strong>The goal of this study was to investigate the structure-activity relationship of tetracaine derivatives and to test a lead compound in a mouse model of CPVT.</p><p><strong>Methods: </strong>We synthesized >200 tetracaine derivatives and characterized 11 of those. The effects of these compounds on Ca<sup>2+</sup> handling in cardiomyocytes from R176Q/+ mice was tested with confocal microscopy. The effects of lead compound MSV1302 on arrhythmia inducibility and cardiac contractility were tested by programmed electrical stimulation and echocardiography, respectively. Plasma and microsomal stability and cytotoxicity assays were also performed.</p><p><strong>Results: </strong>Ca<sup>2+</sup> imaging revealed that 3 of 11 compounds suppressed sarcoplasmic reticulum Ca<sup>2+</sup> leak through mutant RyR2. Two compounds selected for further testing exhibited a half-maximal effective concentration of 146 nM (MSV1302) and 49 nM (MSV1406). Whereas neither compound altered baseline electrocardiogram intervals, only MSV1302 suppressed stress- and pacing-induced ventricular tachycardia in vivo in R176Q/+ mice. Echocardiography revealed that the lead compound MSV1302 did not negatively affect cardiac inotropy and chronotropy. Finally, compound MSV1302 did not block I<sub>Na</sub>, I<sub>Ca,L</sub>, or I<sub>Kr</sub>; it exhibited excellent stability in plasma and microsomes, and it was not cytotoxic.</p><p><strong>Conclusion: </strong>Structure-activity relationship studies of second-generation tetracaine derivatives identified lead compound MSV1302 with a favorable pharmacokinetic profile. MSV1302 normalized aberrant RyR2 activity in vitro and in vivo, without altering cardiac inotropy, chronotropy, or off-target effects on other ion channels. This compound may be a strong candidate for future clinical studies to determine its efficacy in CPVT patients.</p>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo assessment of catheter-tissue contact using tissue proximity indication and its impact on cardiac lesion formation in pulsed field ablation. 在脉冲场消融中使用组织接近度指示器评估导管与组织接触的体内情况及其对心脏病变形成的影响
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-02 DOI: 10.1016/j.hrthm.2024.09.061
Yasuo Okumura, Ryuta Watanabe, Koichi Nagashima, Yuji Wakamatsu, Eric Byun, Qi Chen, Tara Gomez

Background: No evidence exists regarding whether tissue proximity indication (TPI), an impedance-based contact indicator, can improve in vivo lesion formation and durability during pulsed field ablation (PFA).

Objective: This in vivo study investigated the relationship between catheter-tissue contact and lesion formation.

Methods: In 5 porcine subjects, PFA applications were delivered at 35 atrial target sites using the VARIPULSE variable-loop circular catheter with the CARTO 3 mapping system. We compared acute ablative low-voltage zones (LVZs; <0.5 mV), chronic LVZs, and pathologic lesions between no/minimum contact (TPI-negative/flickering TPI-positive status) and consistent tissue contact (consistent TPI-positive status) for typical clinical scenarios and tissue tenting (TPI-positive status with electrodes extensively away from the 3-dimensional mapping surface) for safety margin. Ultrasound imaging also confirmed contact category assessments.

Results: Acute and chronic LVZs were significantly larger with consistent contact compared with no/minimum contact, including pathologic lesion length (36.0 ± 12.5 mm vs 17.4 ± 15.2 mm; P = .002) and maximum width (10.3 ± 2.7 mm vs 5.7 ± 5.1 mm; P = .035); results with tenting (length: 34.6 ± 11.7 mm; width: 11.3 ± 1.9 mm) were comparable to consistent contact. Lesion transmurality was achieved in all lesions with consistent contact or tissue tenting but only in 54.5% with no/minimum contact (P = .001 for each). The TPI-based electrode contact distance, measured as the cumulative length of the multielectrode catheter tip positive for TPI, significantly correlated with lesion length, maximum width, and transmurality.

Conclusion: Consistent TPI-based contact during PFA was strongly associated with distinct chronic transmural lesions, emphasizing the importance of tissue contact in optimizing circumferential lesion formation with circular PFA catheters.

背景:关于基于阻抗的接触指示器--组织接近指示器(TPI)能否改善脉冲场消融(PFA)过程中体内病灶的形成和持久性,目前尚无证据:这项体内研究调查了导管-组织接触与病灶形成之间的关系:在 5 名猪受试者中,使用 VARIPULSE™ 可变环形导管和 CARTO 3™ 绘图系统在 35 个心房靶点进行了 PFA 应用。我们比较了急性消融低电压区(LVZ)的结果:与无/最小接触相比,一致接触的急性和慢性低压区明显更大,包括病理病变长度(36.0±12.5 mm vs 17.4±15.2 mm;P=0.002)和最大宽度(10.3±2.7 mm vs 5.7±5.1 mm;P=0.035),搭帐篷的结果(长度:34.6±11.7;宽度:11.3±1.9 mm)与一致接触相当。一致接触或组织搭帐篷的所有病变都实现了透光性,而无/最小接触的病变只有 54.5% 实现了透光性(P=0.001)。基于 TPI 的电极接触距离是以 TPI 阳性的多电极导管尖端的累积长度来测量的,它与病变长度、最大宽度和透光性显著相关:结论:PFA 过程中基于 TPI 的持续接触与明显的慢性跨膜病变密切相关,这强调了组织接触在优化圆形 PFA 导管周缘病变形成中的重要性。
{"title":"In vivo assessment of catheter-tissue contact using tissue proximity indication and its impact on cardiac lesion formation in pulsed field ablation.","authors":"Yasuo Okumura, Ryuta Watanabe, Koichi Nagashima, Yuji Wakamatsu, Eric Byun, Qi Chen, Tara Gomez","doi":"10.1016/j.hrthm.2024.09.061","DOIUrl":"10.1016/j.hrthm.2024.09.061","url":null,"abstract":"<p><strong>Background: </strong>No evidence exists regarding whether tissue proximity indication (TPI), an impedance-based contact indicator, can improve in vivo lesion formation and durability during pulsed field ablation (PFA).</p><p><strong>Objective: </strong>This in vivo study investigated the relationship between catheter-tissue contact and lesion formation.</p><p><strong>Methods: </strong>In 5 porcine subjects, PFA applications were delivered at 35 atrial target sites using the VARIPULSE variable-loop circular catheter with the CARTO 3 mapping system. We compared acute ablative low-voltage zones (LVZs; <0.5 mV), chronic LVZs, and pathologic lesions between no/minimum contact (TPI-negative/flickering TPI-positive status) and consistent tissue contact (consistent TPI-positive status) for typical clinical scenarios and tissue tenting (TPI-positive status with electrodes extensively away from the 3-dimensional mapping surface) for safety margin. Ultrasound imaging also confirmed contact category assessments.</p><p><strong>Results: </strong>Acute and chronic LVZs were significantly larger with consistent contact compared with no/minimum contact, including pathologic lesion length (36.0 ± 12.5 mm vs 17.4 ± 15.2 mm; P = .002) and maximum width (10.3 ± 2.7 mm vs 5.7 ± 5.1 mm; P = .035); results with tenting (length: 34.6 ± 11.7 mm; width: 11.3 ± 1.9 mm) were comparable to consistent contact. Lesion transmurality was achieved in all lesions with consistent contact or tissue tenting but only in 54.5% with no/minimum contact (P = .001 for each). The TPI-based electrode contact distance, measured as the cumulative length of the multielectrode catheter tip positive for TPI, significantly correlated with lesion length, maximum width, and transmurality.</p><p><strong>Conclusion: </strong>Consistent TPI-based contact during PFA was strongly associated with distinct chronic transmural lesions, emphasizing the importance of tissue contact in optimizing circumferential lesion formation with circular PFA catheters.</p>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of infection and vascular complications with cardiac implantable electronic device implantation in patients with a history of mastectomy 有乳房切除术史的患者植入心脏植入式电子装置后发生感染和血管并发症的风险。
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.hrthm.2024.04.007
{"title":"Risk of infection and vascular complications with cardiac implantable electronic device implantation in patients with a history of mastectomy","authors":"","doi":"10.1016/j.hrthm.2024.04.007","DOIUrl":"10.1016/j.hrthm.2024.04.007","url":null,"abstract":"","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140765387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute effects of dantrolene on the mechanical performance of myopathic human hearts 丹曲林对肌病患者心脏机械性能的急性影响
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.hrthm.2024.03.1815
{"title":"Acute effects of dantrolene on the mechanical performance of myopathic human hearts","authors":"","doi":"10.1016/j.hrthm.2024.03.1815","DOIUrl":"10.1016/j.hrthm.2024.03.1815","url":null,"abstract":"","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140752821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maximum burn prevention practice vs conventional care after direct current cardioversion treatment: The BURN-PREVENTION trial 直流电心脏电复律治疗后的最大烧伤预防实践与常规护理:BURN-PREVENTION 试验。
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.hrthm.2024.03.1818
{"title":"Maximum burn prevention practice vs conventional care after direct current cardioversion treatment: The BURN-PREVENTION trial","authors":"","doi":"10.1016/j.hrthm.2024.03.1818","DOIUrl":"10.1016/j.hrthm.2024.03.1818","url":null,"abstract":"","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140771729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alcohol is neither a risk factor nor a protective factor for sudden cardiac death and/or fatal ventricular arrhythmia: A population-based study with genetic traits and alcohol consumption in the UK Biobank 酒精既不是心脏性猝死和/或致命性室性心律失常的风险因素,也不是其保护因素;一项基于英国生物库中遗传特征和酒精消耗量的人群研究。
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.hrthm.2024.04.097

Background

The association between alcohol consumption and the risk of sudden cardiac death and/or fatal ventricular arrhythmia remains controversial.

Objective

We analyzed the association between alcohol consumption, genetic traits for alcohol metabolism, and the risk of sudden cardiac death and/or fatal ventricular arrhythmia.

Methods

We identified 397,164 individuals enrolled between 2006 and 2010 from the UK Biobank database and followed them until 2021. Alcohol consumption was categorized as current nondrinkers (nondrinkers and ex-drinkers), mild drinkers, moderate drinkers, or heavy drinkers. Genetic traits of alcohol metabolism were stratified according to the polygenic risk score tertiles. The primary and secondary outcomes were a composite of sudden cardiac death and fatal ventricular arrhythmia as well as their individual components.

Results

During follow-up (median 12.5 years), 3543 cases (0.89%) of clinical outcomes occurred. Although mild, moderate, and heavy drinkers showed deceased risks of outcomes compared with current nondrinkers, there was no prognostic difference among nondrinkers, mild drinkers, moderate drinkers, and heavy drinkers. Ex-drinkers showed an increased risk in univariate analysis, but the significance was attenuated after adjusting covariates (hazard ratio 1.19; 95% confidence interval 0.94–1.50). As a continuous variable, alcohol consumption was not associated with clinical outcomes (hazard ratio 1.01; 95% confidence interval 0.99–1.02). Consistent with these findings, there was no association between genetic traits for alcohol metabolism and the risk of clinical outcomes.

Conclusion

Alcohol consumption was neither a protective factor nor a risk factor for sudden cardiac death or fatal ventricular arrhythmia. Genetic traits of alcohol metabolism were not associated with the clinical prognosis.
背景:饮酒与心脏性猝死和/或致命性室性心律失常风险之间的关系仍存在争议:我们分析了饮酒、酒精代谢遗传特征与心脏性猝死和/或致命性室性心律失常风险之间的关系:我们从英国生物库数据库中找到了 2006 年至 2010 年间登记的 397,164 名受试者,并对他们进行了跟踪调查,直至 2021 年。饮酒者分为目前不饮酒者(不饮酒者和曾饮酒者)、轻度饮酒者、中度饮酒者和重度饮酒者。酒精代谢的遗传特征根据多基因风险分级进行分层。主要和次要结果是心脏性猝死和致命性室性心律失常的综合结果,以及它们各自的组成部分:结果:在随访期间(中位数为 12.5 年),共出现了 3 543 例临床结果。虽然与不饮酒者相比,轻度、中度和重度饮酒者出现预后不良的风险较低,但不饮酒者、轻度饮酒者、中度饮酒者和重度饮酒者之间在预后方面没有差异。在单变量分析中,曾饮酒者的风险增加,但在调整协变量后,其显著性有所减弱(危险比(HR)1.19;95% 置信区间[CI]:0.94-1.50):0.94-1.50).作为一个连续变量,饮酒与临床结果无关(HR 1.01;95% CI 0.99-1.02)。与这些研究结果一致,酒精代谢的遗传特征与临床结果风险之间也没有关联:结论:饮酒既不是心脏性猝死或致命性室性心律失常的保护因素,也不是其风险因素。酒精代谢的遗传特征与临床预后无关。
{"title":"Alcohol is neither a risk factor nor a protective factor for sudden cardiac death and/or fatal ventricular arrhythmia: A population-based study with genetic traits and alcohol consumption in the UK Biobank","authors":"","doi":"10.1016/j.hrthm.2024.04.097","DOIUrl":"10.1016/j.hrthm.2024.04.097","url":null,"abstract":"<div><h3>Background</h3><div>The association between alcohol consumption and the risk of sudden cardiac death<span> and/or fatal ventricular arrhythmia remains controversial.</span></div></div><div><h3>Objective</h3><div><span>We analyzed the association between alcohol consumption, genetic traits for alcohol metabolism, and the risk of </span>sudden cardiac death<span> and/or fatal ventricular arrhythmia.</span></div></div><div><h3>Methods</h3><div>We identified 397,164 individuals enrolled between 2006 and 2010 from the UK Biobank<span><span> database and followed them until 2021. Alcohol consumption was categorized as current nondrinkers (nondrinkers and ex-drinkers), mild drinkers, moderate drinkers, or heavy drinkers. Genetic traits of alcohol metabolism were stratified according to the polygenic risk score tertiles. The primary and secondary outcomes were a composite of </span>sudden cardiac death and fatal ventricular arrhythmia as well as their individual components.</span></div></div><div><h3>Results</h3><div>During follow-up (median 12.5 years), 3543 cases (0.89%) of clinical outcomes occurred. Although mild, moderate, and heavy drinkers showed deceased risks of outcomes compared with current nondrinkers, there was no prognostic difference among nondrinkers, mild drinkers, moderate drinkers, and heavy drinkers. Ex-drinkers showed an increased risk in univariate analysis, but the significance was attenuated after adjusting covariates (hazard ratio 1.19; 95% confidence interval 0.94–1.50). As a continuous variable, alcohol consumption was not associated with clinical outcomes (hazard ratio 1.01; 95% confidence interval 0.99–1.02). Consistent with these findings, there was no association between genetic traits for alcohol metabolism and the risk of clinical outcomes.</div></div><div><h3>Conclusion</h3><div>Alcohol consumption was neither a protective factor nor a risk factor for sudden cardiac death or fatal ventricular arrhythmia. Genetic traits of alcohol metabolism were not associated with the clinical prognosis.</div></div>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140851159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When and how to perform venoplasty for lead placement 何时以及如何进行静脉成形术以放置导线。
IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.hrthm.2024.04.088
Because of the increasing use of cardiac implantable electronic devices (CIEDs) with one or more intracardiac electrodes, the rate of lead failure is increasing. Moreover, upgrade of the CIED frequently is indicated for cardiac resynchronization therapy or other reasons. Both these situations require a new intervention, preferably using ipsilateral venous access. However, venous obstruction after CIED insertion occurs in 10%–20% of patients and poses a major obstacle for implantation of additional leads. Possible solutions include lead extraction, contralateral lead insertion, and venoplasty. Preprocedural venoplasty is associated with the lowest short- and long-term risks. Here we describe a step-by-step approach to this technique, which can be introduced and safely performed in most interventional catheterization laboratories.
由于带有一个或多个心内电极的心脏植入式电子设备(CIED)的使用率越来越高,导联故障率也在不断上升。此外,由于心脏再同步化治疗或其他原因,CIED 经常需要升级。这两种情况都需要进行新的干预,最好使用同侧静脉通路。然而,10%-20% 的患者在植入 CIED 后会出现静脉阻塞,这对植入额外的导联构成了重大障碍。可能的解决方案包括拔除导联、插入对侧导联和静脉成形术。术前静脉成形术的短期和长期风险最低。在此,我们将逐步介绍这一技术,大多数介入导管室都可以安全地采用这一技术。
{"title":"When and how to perform venoplasty for lead placement","authors":"","doi":"10.1016/j.hrthm.2024.04.088","DOIUrl":"10.1016/j.hrthm.2024.04.088","url":null,"abstract":"<div><div>Because of the increasing use of cardiac implantable electronic devices (CIEDs) with one or more intracardiac electrodes, the rate of lead failure is increasing. Moreover, upgrade of the CIED frequently is indicated for cardiac resynchronization therapy or other reasons. Both these situations require a new intervention, preferably using ipsilateral venous access. However, venous obstruction after CIED insertion occurs in 10%–20% of patients and poses a major obstacle for implantation of additional leads. Possible solutions include lead extraction, contralateral lead insertion, and venoplasty. Preprocedural venoplasty is associated with the lowest short- and long-term risks. Here we describe a step-by-step approach to this technique, which can be introduced and safely performed in most interventional catheterization laboratories.</div></div>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Heart rhythm
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1